210 related articles for article (PubMed ID: 21245832)
1. Serologic antiglycan antibodies in inflammatory bowel disease.
Lakatos PL; Papp M; Rieder F
Am J Gastroenterol; 2011 Mar; 106(3):406-12. PubMed ID: 21245832
[TBL] [Abstract][Full Text] [Related]
2. Novel anti-glycan antibodies related to inflammatory bowel disease diagnosis and phenotype.
Seow CH; Stempak JM; Xu W; Lan H; Griffiths AM; Greenberg GR; Steinhart AH; Dotan N; Silverberg MS
Am J Gastroenterol; 2009 Jun; 104(6):1426-34. PubMed ID: 19491856
[TBL] [Abstract][Full Text] [Related]
3. New serological markers for inflammatory bowel disease are associated with earlier age at onset, complicated disease behavior, risk for surgery, and NOD2/CARD15 genotype in a Hungarian IBD cohort.
Papp M; Altorjay I; Dotan N; Palatka K; Foldi I; Tumpek J; Sipka S; Udvardy M; Dinya T; Lakatos L; Kovacs A; Molnar T; Tulassay Z; Miheller P; Norman GL; Szamosi T; Papp J; ; Lakatos PL
Am J Gastroenterol; 2008 Mar; 103(3):665-81. PubMed ID: 18047543
[TBL] [Abstract][Full Text] [Related]
4. Prevalence and diagnostic role of antineutrophil cytoplasmic antibodies in inflammatory bowel disease.
Bansi DS; Chapman RW; Fleming KA
Eur J Gastroenterol Hepatol; 1996 Sep; 8(9):881-5. PubMed ID: 8889455
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease.
Peeters M; Joossens S; Vermeire S; Vlietinck R; Bossuyt X; Rutgeerts P
Am J Gastroenterol; 2001 Mar; 96(3):730-4. PubMed ID: 11280542
[TBL] [Abstract][Full Text] [Related]
6. Serologic testing with ANCA, ASCA, and anti-OmpC in children and young adults with Crohn's disease and ulcerative colitis: diagnostic value and correlation with disease phenotype.
Zholudev A; Zurakowski D; Young W; Leichtner A; Bousvaros A
Am J Gastroenterol; 2004 Nov; 99(11):2235-41. PubMed ID: 15555007
[TBL] [Abstract][Full Text] [Related]
7. [Assessment of usefulness of anti-Saccharomyces cerevisiae and anti-neutrophil cytoplasmic antibodies in patients with unspecific inflammatory bowel diseases].
Mokrowiecka A; Gasiorowska A; Małecka-Panas E
Pol Merkur Lekarski; 2004; 17 Suppl 1():22-6. PubMed ID: 15603341
[TBL] [Abstract][Full Text] [Related]
8. Anticarbohydrate antibodies as markers of inflammatory bowel disease in a Central European cohort.
Malickova K; Lakatos PL; Bortlik M; Komarek V; Janatkova I; Lukas M
Eur J Gastroenterol Hepatol; 2010 Feb; 22(2):144-50. PubMed ID: 19927001
[TBL] [Abstract][Full Text] [Related]
9. Serologic markers in inflammatory bowel disease (IBD).
Nakamura RM; Barry M
MLO Med Lab Obs; 2001 Nov; 33(11):8-15; quiz 16-9. PubMed ID: 11721286
[TBL] [Abstract][Full Text] [Related]
10. [Relevance of serologic studies in inflammatory bowel diseases].
Papp M; Altorjay I; Lakatos PL
Orv Hetil; 2007 May; 148(19):887-96. PubMed ID: 17478404
[TBL] [Abstract][Full Text] [Related]
11. Serologic markers: impact on early diagnosis and disease stratification in inflammatory bowel disease.
Arai R
Postgrad Med; 2010 Jul; 122(4):177-85. PubMed ID: 20675980
[TBL] [Abstract][Full Text] [Related]
12. Influence of phenotype at diagnosis and of other potential prognostic factors on the course of inflammatory bowel disease.
Romberg-Camps MJ; Dagnelie PC; Kester AD; Hesselink-van de Kruijs MA; Cilissen M; Engels LG; Van Deursen C; Hameeteman WH; Wolters FL; Russel MG; Stockbrügger RW
Am J Gastroenterol; 2009 Feb; 104(2):371-83. PubMed ID: 19174787
[TBL] [Abstract][Full Text] [Related]
13. Relationship between ANCA and clinical activity in inflammatory bowel disease: variation in prevalence of ANCA and evidence of heterogeneity.
Abad E; Tural C; Mirapeix E; Cuxart A
J Autoimmun; 1997 Apr; 10(2):175-80. PubMed ID: 9185879
[TBL] [Abstract][Full Text] [Related]
14. Differentiating ulcerative colitis from Crohn disease in children and young adults: report of a working group of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the Crohn's and Colitis Foundation of America.
; ; Bousvaros A; Antonioli DA; Colletti RB; Dubinsky MC; Glickman JN; Gold BD; Griffiths AM; Jevon GP; Higuchi LM; Hyams JS; Kirschner BS; Kugathasan S; Baldassano RN; Russo PA
J Pediatr Gastroenterol Nutr; 2007 May; 44(5):653-74. PubMed ID: 17460505
[TBL] [Abstract][Full Text] [Related]
15. C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study.
Henriksen M; Jahnsen J; Lygren I; Stray N; Sauar J; Vatn MH; Moum B;
Gut; 2008 Nov; 57(11):1518-23. PubMed ID: 18566104
[TBL] [Abstract][Full Text] [Related]
16. New serologic markers for inflammatory bowel disease diagnosis.
Dotan I
Dig Dis; 2010; 28(3):418-23. PubMed ID: 20926866
[TBL] [Abstract][Full Text] [Related]
17. Inflammatory bowel diseases: controversies in the use of diagnostic procedures.
Vucelic B
Dig Dis; 2009; 27(3):269-77. PubMed ID: 19786751
[TBL] [Abstract][Full Text] [Related]
18. Antibodies against laminaribioside and chitobioside are novel serologic markers in Crohn's disease.
Dotan I; Fishman S; Dgani Y; Schwartz M; Karban A; Lerner A; Weishauss O; Spector L; Shtevi A; Altstock RT; Dotan N; Halpern Z
Gastroenterology; 2006 Aug; 131(2):366-78. PubMed ID: 16890590
[TBL] [Abstract][Full Text] [Related]
19. IgG oligosaccharide alterations are a novel diagnostic marker for disease activity and the clinical course of inflammatory bowel disease.
Shinzaki S; Iijima H; Nakagawa T; Egawa S; Nakajima S; Ishii S; Irie T; Kakiuchi Y; Nishida T; Yasumaru M; Kanto T; Tsujii M; Tsuji S; Mizushima T; Yoshihara H; Kondo A; Miyoshi E; Hayashi N
Am J Gastroenterol; 2008 May; 103(5):1173-81. PubMed ID: 18177457
[TBL] [Abstract][Full Text] [Related]
20. Serum antibodies for the diagnosis of inflammatory bowel disease: ANCA for ulcerative colitis and ASCA for Crohn's disease.
Tecnologica MAP Suppl; 1999 Jun; ():18-20. PubMed ID: 10848041
[No Abstract] [Full Text] [Related]
[Next] [New Search]